Form 4: Director Sean Ellis Boosts Entera Bio Stake

Entera Bio Ltd. Director Sean Ellis acquired 18,000 ordinary shares at a weighted average price of $1.24, increasing his direct beneficial ownership to 178,098 shares.

Summary

• Sean Ellis, a Director of Entera Bio Ltd. (ENTX), purchased 18,000 ordinary shares.
• The transaction occurred on February 9, 2026, at a weighted average price of $1.24 per share.
• The purchase price ranged from $1.18 to $1.299 per share.
• Following this transaction, Sean Ellis directly beneficially owns 178,098 ordinary shares of Entera Bio Ltd.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as insider buying typically reflects management's confidence in the company's future, though it is a single transaction.

Positives

• A Director's purchase of company shares signals confidence in the company's future prospects and valuation.
• The acquisition increases insider ownership, potentially aligning management interests more closely with shareholders.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that insider buying, such as this transaction by a Director, is often interpreted by the market as a positive signal, indicating that those with intimate knowledge of the company believe its shares are undervalued or expect positive developments. This can sometimes precede periods of positive share price performance, depending on the broader market and company-specific news flow.

Related Party Transactions

• Director Sean Ellis, a related party, acquired 18,000 ordinary shares of Entera Bio Ltd. at a weighted average price of $1.24 per share.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive indicator of management's belief in the company's value and future prospects, potentially boosting investor confidence.

Key Dates

Recommendation

While insider buying is generally a positive signal, indicating management's confidence in the company's valuation, this Form 4 alone does not provide sufficient comprehensive financial data to warrant a 'buy' recommendation. A seasoned investor would likely 'hold' and monitor for further developments or a broader financial review before making a stronger commitment.

Keywords

Entera Bio, ENTX, Sean Ellis, Insider Trading, Form 4, Share Purchase, Director Ownership, Biotechnology